These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 2157841)
1. Cystic ovarian necrosis complicating tamoxifen therapy for breast cancer in a premenopausal woman. A case report. Jolles CJ; Smotkin D; Ford KL; Jones KP J Reprod Med; 1990 Mar; 35(3):299-300. PubMed ID: 2157841 [TBL] [Abstract][Full Text] [Related]
2. Ovarian cyst torsion and extreme ovarian stimulation in a premenopausal patient treated with tamoxifen for ductal carcinoma in situ of the breast. Taran A; Eggemann H; Costa SD; Smith B; Bischoff J Am J Obstet Gynecol; 2006 Oct; 195(4):e5-6. PubMed ID: 17000228 [TBL] [Abstract][Full Text] [Related]
3. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients. Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302 [TBL] [Abstract][Full Text] [Related]
4. Tamoxifen withdrawal response. Report of a case. Belani CP; Pearl P; Whitley NO; Aisner J Arch Intern Med; 1989 Feb; 149(2):449-50. PubMed ID: 2537066 [TBL] [Abstract][Full Text] [Related]
5. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Yen TW; Hunt KK; Mirza NQ; Thomas ES; Singletary SE; Babiera GV; Meric-Bernstam F; Buchholz TA; Feig BW; Ross MI; Ames FC; Theriault RL; Kuerer HM Cancer; 2004 Mar; 100(5):942-9. PubMed ID: 14983489 [TBL] [Abstract][Full Text] [Related]
6. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma. Nakhlis F; Lazarus L; Hou N; Acharya S; Khan SA; Staradub VL; Rademaker AW; Morrow M J Am Coll Surg; 2005 Nov; 201(5):688-94. PubMed ID: 16256910 [TBL] [Abstract][Full Text] [Related]
7. [Radiotherapy and tamoxifen facilitate breast-preserving treatment of ductal carcinoma in situ of the breast]. Sautter-Bihl ML Strahlenther Onkol; 1999 Dec; 175(12):620-1. PubMed ID: 10633790 [No Abstract] [Full Text] [Related]
9. Ovarian cysts in tamoxifen-treated women with breast cancer. Inal MM; Incebiyik A; Sanci M; Yildirim Y; Polat M; Pilanci B; Nayki C; Camuzcuoğlu H Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):104-6. PubMed ID: 15866095 [TBL] [Abstract][Full Text] [Related]
10. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Sawka CA; Pritchard KI; Paterson AH; Sutherland DJ; Thomson DB; Shelley WE; Myers RE; Mobbs BG; Malkin A; Meakin JW Cancer Res; 1986 Jun; 46(6):3152-6. PubMed ID: 3084082 [TBL] [Abstract][Full Text] [Related]
11. Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer. Hubalek M; Ramoni A; Mueller-Holzner E; Marth C Gynecol Oncol; 2004 Oct; 95(1):264-6. PubMed ID: 15385144 [TBL] [Abstract][Full Text] [Related]
12. MR appearance of endometrial carcinoma and mucinous cystadenoma in a postmenopausal patient treated with tamoxifen for breast cancer. Joja I; Asakawa T; Ando Y; Shiraiwa M; Shibutani O; Akaki S; Kuroda M; Mizutani Y; Kudo T; Hiraki Y Radiat Med; 1998; 16(4):315-9. PubMed ID: 9814431 [TBL] [Abstract][Full Text] [Related]
13. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer. Rodríguez-Rodríguez LM; Rodríguez-Rodríguez EM; Oramas-Rodríguez JM; Santolaria-Fernandez F; Llanos M; Cruz J; Martínez A; González-Reimers E; Gómez A; Batista N Breast Cancer Res Treat; 2005 Sep; 93(1):75-83. PubMed ID: 16184462 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Sverrisdottir A; Nystedt M; Johansson H; Fornander T Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828 [TBL] [Abstract][Full Text] [Related]
15. Tamoxifen as systemic treatment of advanced breast cancer during pregnancy--case report and literature review. Isaacs RJ; Hunter W; Clark K Gynecol Oncol; 2001 Mar; 80(3):405-8. PubMed ID: 11263941 [TBL] [Abstract][Full Text] [Related]
16. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases. El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812 [TBL] [Abstract][Full Text] [Related]
17. Exacerbation of endometriosis as a result of premenopausal tamoxifen exposure. Rose PG; Alvarez B; Maclennan GT Am J Obstet Gynecol; 2000 Aug; 183(2):507-8. PubMed ID: 10942499 [TBL] [Abstract][Full Text] [Related]
18. Granulosa cell tumor of the ovary associated with antecedent tamoxifen use. Gherman RB; Parker MF; Macri CI Obstet Gynecol; 1994 Oct; 84(4 Pt 2):717-9. PubMed ID: 9205462 [TBL] [Abstract][Full Text] [Related]
19. Detection of endometrial cancer in asymptomatic postmenopausal breast cancer patient treated with tamoxifen: a case report. Sinawat S; Chiyabutra T; Kleabkaew P J Med Assoc Thai; 2001 Jul; 84(7):1033-6. PubMed ID: 11759963 [TBL] [Abstract][Full Text] [Related]
20. Tamoxifen and hypercalcaemia. A case report. Bezwoda WR; Derman D; Zaltzman M; de Moor NG; Lange M S Afr Med J; 1980 Nov; 58(20):821-2. PubMed ID: 6255614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]